IDEXX CEO Jonathan Mazelsky Plans To Sell 25,140 Shares Worth $17.7 Million

The planned sale of IDEXX stock follows a same-day option exercise, and the shares are down about 7% over 12 months as of Tuesday's close.

Share
IDEXX CEO Jonathan Mazelsky Plans To Sell 25,140 Shares Worth $17.7 Million

Jonathan Jay Mazelsky, president and CEO of IDEXX Laboratories, plans to sell 25,140 shares with a stated aggregate market value of $17.7 million, according to a Form 144, the notice insiders file before a planned sale. IDEXX makes diagnostic products and services mainly for veterinary clinics, livestock, poultry and dairy producers, and water testing.

Option exercise feeds the sale

The shares come from a stock option exercise, which the filing says was acquired from the issuer on 11/04/2026 and paid for in cash. The approximate sale date listed is also 11/04/2026.

Morgan Stanley Smith Barney LLC Executive Financial Services is the named broker. The filing lists Mazelsky as both an officer and a director of the company.

Where the stock stands

IDXX closed at $672.04 on Tuesday, the session before the filing, and at $698.55 on Wednesday. The shares were down about 0.7% this year and about 7% over the past 12 months as of Tuesday's close, within a 52-week range of $500.61 to $769.98.

IDEXX's largest business is its Companion Animal Group, which sells in-clinic analyzers, rapid test kits, reference laboratory testing, and practice management and imaging software to veterinarians. It also runs water-testing and livestock, poultry and dairy segments, according to its annual report for the year ended December 31, 2025.

Whether the sale is carried out would show up in a later insider transaction filing.

Sources

More on IDEXX Laboratories

All IDEXX Laboratories (IDXX) coverage →